High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI‐2) is an independent marker for shorter progression‐free survival in patients with early stage …
J Nordengren, MF Lidebring… - … journal of cancer, 2002 - Wiley Online Library
Previous studies including various tumor types have shown different associations between
tumor tissue levels of plasminogen activator inhibitor 2 (PAI-2) and patient survival. High …
tumor tissue levels of plasminogen activator inhibitor 2 (PAI-2) and patient survival. High …
TP53 protein expression analysis by luminometric immunoassay in comparison with gene mutation status and prognostic factors in early stage endometrial cancer
…, PO Bendahl, Ĺ Borg, M Fernö, MF Lidebring… - International Journal of …, 2002 - ijgc.bmj.com
Mutations in the TP53 tumor suppressor gene have been shown to significantly correlate
with poor prognosis in endometrial cancer. In the present study we have evaluated a …
with poor prognosis in endometrial cancer. In the present study we have evaluated a …
This issue's topics
…, SM Tan, KL Cheung, PC Willsher, MF Lidebring… - 2001 - ejcancer.com
In this issue, Alexander Eggermont reviews the current evidence for the use of the
pleiotropic cytokine interferon-alpha (IFN-α) in the treatment of malignant melanoma. He …
pleiotropic cytokine interferon-alpha (IFN-α) in the treatment of malignant melanoma. He …
[CITATION][C] CANCER DIAGNOSIS AND THERAPY-High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter …
J Nordengren, MF Lidebring… - International …, 2002 - New York, NY [etc.]: Alan R. Liss, Inc.